Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials

Main Article Content

Richard Langley
Diamant Thaci
Andrew Blauvelt
Tsen-Fang Tsai
Megan Miller
Jenny Yu
Yaung-Kaung Shen
Yin You
Ya-Wen Yang
Kim Papp
Luis Puig
Peter Foley

Keywords

psoriasis

Abstract

N/A

References

1. Armstrong AW et al. Am J Clin Dermatol. 2016;17:329-36;

2. Shalom G et al. J Dermatolog Treat.
2019;30:534-9;

3. Kalb RE et al. JAMA Dermatol. 2015;151:961-9;

4. Blauvelt A et al. J Am Acad
Dermatol. 2017;76:405-17; 5. Reich K et al. J Am Acad Dermatol. 2017;76:418-31.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>